Pembrolizumab (MK-3475) versus platinum-based chemotherapy for PD-L1+non-small cell lung cancer (NSCLC): Randomized, open-label, phase 3 KEYNOTE-042 study

被引：0
|
作者：
Mok, T. [1 ]
Wu, Y. -L. [2 ,3 ]
Sadowski, S. [4 ]
Zhang, J. [5 ]
Rangwala, R. [4 ]
de Lima Lopes, G. [6 ,7 ]
机构：
[1] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[4] Merck & Co Inc, Clin Oncol, Kenilworth, NJ USA
[5] Merck & Co Inc, BARDS, Kenilworth, NJ USA
[6] Oncoclin Brasil Grp, Oncol, Sao Paulo, Brazil
[7] Johns Hopkins Univ, Sao Paulo, Brazil
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
481TiP
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [41] A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer
    Herbst, Roy S.
    Gurpide, Alfonso
    Surmont, Veerle
    Kim, Dong-Wan
    Waqar, Salem Naheed
    Herder, Judith
    Lee, Dae Ho
    Carcereny, Enric
    Reguart, Naomi
    Wallmark, John M.
    Ramalingam, Suresh S.
    Langer, Corey J.
    Lubiniecki, Gregory M.
    Knowles, James
    Zhou, Honghong
    Hanson, Mary Elizabeth
    Baas, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small-cell lung cancer: a multicenter, randomized, open-label Phase II study
    Babu, K. Govind
    Prabhash, Kumar
    Vaid, Ashok K.
    Sirohi, Bhawna
    Diwakar, Ravi B.
    Rao, Raghunadha
    Kar, Madhuchanda
    Malhotra, Hemant
    Nag, Shona
    Goswami, Chanchal
    Raina, Vinod
    Mohan, Ravi
    ONCOTARGETS AND THERAPY, 2014, 7 : 1051 - 1060
  • [43] Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: A phase II, open-label, multicenter, randomized study
    Prabhash, Kumar
    Babu, Kanaka Govind
    Vaid, Ashok K.
    Rangaraju, Ranga Rao
    Sirohi, Bhawna
    Diwakar, Ravi
    Rao, Raghunadha
    Kar, Madhuchanda
    Malhotra, Hemant
    Nag, Shona Milon
    Goswami, Chanchal
    Raina, Vinod
    Mohan, Pedapenki Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
    Chan, A. T. C.
    Lee, V. H. F.
    Hong, R-L
    Ahn, M. -J.
    Chong, W. Q.
    Kim, S. -B.
    Ho, G. F.
    Caguioa, P. B.
    Ngamphaiboon, N.
    Ho, C.
    Aziz, M. A. S. A.
    Ng, Q. S.
    Yen, C. -J.
    Soparattanapaisarn, N.
    Ngan, R. K. -C
    Kho, S. K.
    Tiambeng, M. L. A.
    Yun, T.
    Sriuranpong, V.
    Algazi, A. P.
    Cheng, A.
    Massarelli, E.
    Swaby, R. F.
    Saraf, S.
    Yuan, J.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2023, 34 (03) : 251 - 261
  • [45] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
    Reck, Martin
    Rodriguez-Abreu, Delvys
    Robinson, Andrew G.
    Hui, Rina
    Csoszi, Tibor
    Fulop, Andrea
    Gottfried, Maya
    Peled, Nir
    Tafreshi, Ali
    Cuffe, Sinead
    O'Brien, Mary
    Rao, Suman
    Hotta, Katsuyuki
    Leiby, Melanie A.
    Lubiniecki, Gregory M.
    Shentu, Yue
    Rangwala, Reshma
    Brahmer, Julie R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1823 - 1833
  • [46] Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1 positive advanced non small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies
    Nosaki, Kaname
    Saka, Hideo
    Hosomi, Yukio
    Baas, Paul
    de Castro, Gilberto, Jr.
    Reck, Martin
    Wu, Yi-Long
    Brahmer, Julie R.
    Felip, Enriqueta
    Sawada, Takeshi
    Noguchi, Kazuo
    Han, Shi Rong
    Piperdi, Bilal
    Kush, Debra A.
    Lopes, Gilberto
    LUNG CANCER, 2019, 135 : 188 - 195
  • [47] A phase III, randomized, open-label trial of nivolumab (anti-PD-1) ; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+non-small cell lung cancer (NSCLC)
    Carbone, David Paul
    Socinski, Mark A.
    Chen, Allen C.
    Bhagavatheeswaran, Prabhu
    Reck, Marlin
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] Pembrolizumab in Combination With Platinum-Based Chemotherapy in Recurrent EGFR/ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
    Gadgeel, S.
    Dziubek, K.
    Nagasaka, M.
    Braun, T.
    Hassan, K.
    Cheng, H.
    Wozniak, A.
    Halmos, B.
    Stevenson, J.
    Patil, P.
    Pennell, N.
    Fidler, M. J.
    Bonomi, P.
    Qin, A.
    Niu, Z.
    Nagrath, S.
    Kalemkerian, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S863 - S863
  • [49] First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
    Soria, Jean-Charles
    Tan, Daniel S. W.
    Chiari, Rita
    Wu, Yi-Long
    Paz-Ares, Luis
    Wolf, Juergen
    Geater, Sarayut L.
    Orlov, Sergey
    Cortinovis, Diego
    Yu, Chong-Jen
    Hochmair, Maximillian
    Cortot, Alexis B.
    Tsai, Chun-Ming
    Moro-Sibilot, Denis
    Campelo, Rosario G.
    McCulloch, Tracey
    Sen, Paramita
    Dugan, Margaret
    Pantano, Serafino
    Branle, Fabrice
    Massacesi, Cristian
    de Castro, Gilberto, Jr.
    LANCET, 2017, 389 (10072): : 917 - 929
  • [50] KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer
    Reck, M.
    Rodriguez-Abreu, D.
    Robinson, A. G.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M.
    Rao, S.
    Hotta, K.
    Garay, T.
    Jensen, E.
    Ebiana, V.
    Brahmer, J. R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S243 - S243
12345